Novartis plans to invest $23 billion over the next five years to expand its manufacturing and research in the U.S. The investment will cover more than 10 facilities, including seven new sites, and ...

Swiss pharmaceutical company, Novartis, has announced plans to build a new, $1.1 billion biomedical research complex in San ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...

While FDA drug and device reviewers and inspectors were protected from layoffs, drug reviews are likely to be affected, ...

The Business Research Company's Radiotherapy Induced Oral Mucositis Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED ...

US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was speaking as he announced 25% tariffs on cars and car parts imported into the US.

The NFL named Novartis as its first-in-category corporate pharmaceutical partner. Together, the two organizations will work to promote healthy choices and making active decisions in regard to ...

Novartis has announced positive results from a late-stage programme of its experimental gene replacement therapy in patients with the rare neuromuscular disease spinal muscular atrophy (SMA). The ...

Novartis intends to submit an approval application by the end of June. In addition to STEER, the Swiss pharmaceutical giant has data from experiments dubbed “STRONG” and “STRENGTH.” The former was an ...

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...